Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.
Raghunand N, Scicinski J, Guntle GP, Jagadish B, Mash EA, Bruckheimer E, Oronsky B, Korn RL. Raghunand N, et al. Among authors: scicinski j. Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254266 Free PMC article.
No patient left behind: The promise of immune priming with epigenetic agents.
Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. Carter CA, et al. Among authors: scicinski j. Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Oncoimmunology. 2017. PMID: 29123948 Free PMC article. Review.
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. Zhao H, et al. Among authors: scicinski j. Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017. Clin Epigenetics. 2017. PMID: 28149332 Free PMC article.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. Oronsky B, et al. Among authors: scicinski j. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Expert Opin Investig Drugs. 2017. PMID: 27935336 Free article. Review.
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA. Brzezniak C, et al. Among authors: scicinski j. Oncol Res Treat. 2016;39(11):720-723. doi: 10.1159/000449432. Epub 2016 Sep 19. Oncol Res Treat. 2016. PMID: 27855386
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.
Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. Oronsky B, et al. Among authors: scicinski j. Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016. Clin Med Insights Oncol. 2016. PMID: 27840583 Free PMC article.
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC. Das DS, et al. Among authors: scicinski j. Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. Epub 2016 Apr 27. Leukemia. 2016. PMID: 27118403 Free PMC article.
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B. Carter CA, et al. Among authors: scicinski j. Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Oncotarget. 2016. PMID: 27007055 Free PMC article. Review.
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.
Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C. Carter CA, et al. Among authors: scicinski j. Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug. Case Rep Oncol. 2016. PMID: 27403127 Free PMC article.
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.
Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. Oronsky B, et al. Among authors: scicinski j. Biomolecules. 2016 Jul 4;6(3):32. doi: 10.3390/biom6030032. Biomolecules. 2016. PMID: 27384589 Free PMC article. Review.
70 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback